ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

3 links0 made here, not in the record4 judgments2 judges (the rules as one: Rule based)8 record changes seen
GPT-6 Astra (Medium)Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06577441Testing the Addition of anIDH2 Inhibitor, Enasidenib,to Usual Treatment(Cedazuridine-Decitabine)for Higher-RiskMyelodysplastic Syndrome(MDS) With IDH2 Mutation (ANational Cancer Institute (NCIPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 6 · ClinicalTrials.gov record · Version of 2026-10-06Oct 22 · ClinicalTrials.gov record · Version of 2026-10-22Oct 26 · ClinicalTrials.gov record · Version of 2026-10-26Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Nov 4 · ClinicalTrials.gov record · Version of 2026-11-04Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSMyelodysplastic SyndromesThe registry's MeSH filing›Oct 20 · GPT-6 Astra (Medium) · RightAs of now · Rule based · Main conditionMain conditionDRUGSINT001926Entry “Decitabine and Cedazuridine”, …›Nov 18 · Rule based · BackgroundBackgroundEnasidenibIntervention entry›Nov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Myelodysplastic Syndromes

From the registry record2 judgments on this link
Fit of the first condition term, from the registry to what was judged
RegistryMyelodysplastic Syndromes, as filedthe registry files the study under it
→judged
Main condition (R9)

All judgments on this study

WhenLinkJudgeDecisionState
Oct 2The record itselfClinicalTrials.gov recordVersion of 2026-10-02Record change
Oct 5The record itselfClinicalTrials.gov recordVersion of 2026-10-05Record change
Oct 6The record itselfClinicalTrials.gov recordVersion of 2026-10-06Record change
Oct 20Myelodysplastic SyndromesGPT-6 Astra (Medium)RightCurrent
Oct 22The record itselfClinicalTrials.gov recordVersion of 2026-10-22Record change
Oct 26The record itselfClinicalTrials.gov recordVersion of 2026-10-26Record change
Nov 2The record itselfClinicalTrials.gov recordVersion of 2026-11-02Record change
Nov 4The record itselfClinicalTrials.gov recordVersion of 2026-11-04Record change
Nov 18The record itselfClinicalTrials.gov recordVersion of 2026-11-18Record change
Nov 18INT001926Rule based · role ruleBackgroundCurrent
Nov 18EnasidenibRule based · role ruleTestedCurrent
As of nowMyelodysplastic SyndromesRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.